Value through Innovation27 July 2016

Clinical Study Results

  • Afatinib + Nintedanib - Colorectal Neoplasms
    Clinical Study Number 1239.2
    Study Indication Colorectal Neoplasms
    Product Afatinib + Nintedanib
    Generic Name Afatinib + Nintedanib
    Lab Code
    Clinical Phase II
    Study Title

    A phase II trial of weekly alternating sequential administration of BIBF 1120 and BIBW 2992 in patients with advanced colorectal cancer

    Study Document Trial synopsis 1239.2_DR english
  • GIOTRIF ® (afatinib) - Colorectal Neoplasms
    Clinical Study Number 1200.74
    Study Indication Colorectal Neoplasms
    Product GIOTRIF ® (afatinib)
    Generic Name Afatinib
    Lab Code
    Clinical Phase II
    Study Title

    An open label, partially randomised Phase II trial to investigate the efficacy and   safety of BIBW 2992 in patients with metastatic colorectal cancer who never   received prior anti-EGFR treatment

    Study Document Triall synopsis 1200.74_DR english
  • VARGATEF ® - Colorectal Neoplasms
    Clinical Study Number 1199.51
    Study Indication Colorectal Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I/II
    Study Title

    A phase I-II study of BIBF 1120 and Folfox compared to Bevacizumab and Folfox in first line metastatic colorectal cancer patients

    Study Document Trial synopsis 1199.51_DR english
  • Sibrotuzumab - Colorectal Neoplasms
    Clinical Study Number 1152.10
    Study Indication Colorectal Neoplasms
    Product Sibrotuzumab
    Generic Name Sibrotuzumab
    Lab Code
    Clinical Phase IIa
    Study Title

    A phase II uncontrolled study to evaluate the antitumour activity and safety of intravenous BIBH 1, administered in a weekly dose of 100 mg in 12 weeks, in patients with metastatic colorectal cancer.

    Study Document Trial synopsis 1152.10_CO english
  • VARGATEF ® - Colorectal Neoplasms
    Clinical Study Number 1199.52
    Study Indication Colorectal Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase III
    Study Title

    A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies

    Study Document Trial synopsis 1199.52_PR english Lay summary 1199.52 english
  • Afatinib + Nintedanib - Colorectal Neoplasms
    Clinical Study Number 1239.6
    Study Indication Colorectal Neoplasms
    Product Afatinib + Nintedanib
    Generic Name Afatinib + Nintedanib
    Lab Code
    Clinical Phase II
    Study Title

    A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer

    Study Document Trial statement 1239.6 english
  • VARGATEF ® - Colorectal Neoplasms
    Clinical Study Number 1199.251
    Study Indication Colorectal Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase II
    Study Title

    LUME-Colon 2: An open-label randomized phase II study to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer

    Study Document Trial synopsis 1199.251 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.